AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34000112 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist Comprehensive Medication Management Services (PCS)
Number of subjects: 120
Study 34000112 — intervention group
Group type: COMPARATOR
Intervention: Modified or No CMM Services (NCS)
Number of subjects: 120
Study 34000112 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist Comprehensive Medication Management Services (PCS) and Modified or No CMM Services (NCS)
Number of subjects: 120
Study 32925435 — intervention group
Group type: EXPERIMENTAL
Intervention: IVRA with 300 mg lidocaine
Number of subjects: 120
Study 32925435 — intervention group
Group type: COMPARATOR
Intervention: Axillary block with 280 mg mepivacaine
Number of subjects: 120
Study 32925435 — intervention group
Group type: EXPERIMENTAL
Intervention: IVRA
Number of subjects: 120
Study 32925435 — intervention group
Group type: COMPARATOR
Intervention: Axillary block
Number of subjects: 120
Study 34391588 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT)
Number of subjects: 539
Study 33258422 — intervention group
Group type: EXPERIMENTAL
Intervention: ENABLE CHF-PC intervention
Number of subjects: 415
Study 33320964 — intervention group
Group type: EXPERIMENTAL
Intervention: COSIMO model-derived screening for colorectal cancer
Number of subjects: 0
Study 35641112 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 188
Study 35641112 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 188
Study 33675672 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirror therapy along with a Stroke rehabilitation program
Number of subjects: 38
Study 33675672 — intervention group
Group type: COMPARATOR
Intervention: Stroke rehabilitation program without mirror therapy
Number of subjects: 38
Study 32221086 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-adhesive breast prostheses
Number of subjects: 30
Study 32221086 — intervention group
Group type: COMPARATOR
Intervention: Conventional breast prostheses
Number of subjects: 30
Study 35286136 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab plus standard chemotherapy
Number of subjects: 1000
Study 35286136 — intervention group
Group type: COMPARATOR
Intervention: Standard chemotherapy alone
Number of subjects: 1000
Study 33967022 — intervention group
Group type: EXPERIMENTAL
Intervention: Age group 20–64 years
Number of subjects: 230
Study 33967022 — intervention group
Group type: EXPERIMENTAL
Intervention: Age group 65–84 years
Number of subjects: 230
Study 33967022 — intervention group
Group type: EXPERIMENTAL
Intervention: Age group 85+ years
Number of subjects: 230
Study 32794334 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-determined maximal axial diameter (MAD) of cervical lymph nodes = 4 cm in the training group (n = 1033)
Number of subjects: 2066
Study 32794334 — intervention group
Group type: EXPERIMENTAL
Intervention: MAD = 4 cm classified as N3 in the N classification
Number of subjects: 2066
Study 32794334 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed N staging system
Number of subjects: 2066
Study 35696601 — intervention group
Group type: EXPERIMENTAL
Intervention: Local Vibration Therapy (VT) for 10 minutes at 45 Hz, starting 1 hour post-exercise, applied twice daily for 48 hours
Number of subjects: 10
Study 35696601 — intervention group
Group type: COMPARATOR
Intervention: Control group (no local VT)
Number of subjects: 10
Study 35696601 — intervention group
Group type: EXPERIMENTAL
Intervention: Local Vibration Therapy (VT)
Number of subjects: 10
Study 33522961 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity exercise
Number of subjects: 99
Study 33522961 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise
Number of subjects: 99
Study 33522961 — intervention group
Group type: COMPARATOR
Intervention: Inactive control
Number of subjects: 99
Study 34250916 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS + VR
Number of subjects: 20
Study 34250916 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS + VR
Number of subjects: 20
Study 33510503 — intervention group
Group type: EXPERIMENTAL
Intervention: Substandard medicines found in health facilities
Number of subjects: 88
Study 33510503 — intervention group
Group type: EXPERIMENTAL
Intervention: Labeling and storage conditions of medicines
Number of subjects: 88
Study 33510503 — intervention group
Group type: EXPERIMENTAL
Intervention: Storage requirements compliance
Number of subjects: 88
Study 34621011 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide 160 mg/day plus androgen deprivation therapy (ADT)
Number of subjects: 139
Study 34621011 — intervention group
Group type: COMPARATOR
Intervention: Bicalutamide 50 mg/day plus ADT
Number of subjects: 139
Study 33556352 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga classes
Number of subjects: 320
Study 33556352 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy (PT) sessions
Number of subjects: 320
Study 33556352 — intervention group
Group type: COMPARATOR
Intervention: Education (control group)
Number of subjects: 320
Study 33556352 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments (yoga, PT, education)
Number of subjects: 320
Study 36198143 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittently scanned continuous glucose monitoring
Number of subjects: 156
Study 36198143 — intervention group
Group type: COMPARATOR
Intervention: Fingerstick testing (usual-care group)
Number of subjects: 156
Study 33538520 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen signature in the tumor microenvironment
Number of subjects: 416
Study 33538520 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen signature based on 3 features
Number of subjects: 416
Study 33538520 — intervention group
Group type: COMPARATOR
Intervention: Clinicopathological model (4 risk factors: obstruction or perforation, lymphovascular invasion, tumor budding, no chemotherapy)
Number of subjects: 416
Study 32139135 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex 2 mg kg‐1
Number of subjects: 200
Study 32139135 — intervention group
Group type: COMPARATOR
Intervention: Neostigmine 0.07 mg kg‐1 (maximum 5 mg)
Number of subjects: 200
Study 34716106 — intervention group
Group type: EXPERIMENTAL
Intervention: Honey gargling every six hours for ten days
Number of subjects: 24
Study 34716106 — intervention group
Group type: COMPARATOR
Intervention: Placebo gargling every six hours for ten days
Number of subjects: 24
Study 34716106 — intervention group
Group type: COMPARATOR
Intervention: Standard post-operative regimens
Number of subjects: 24
Study 34411252 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline opioid use
Number of subjects: 241
Study 32964675 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted BMI
Number of subjects: 850000
Study 32964675 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted WHR
Number of subjects: 850000
Study 32964675 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted WHRadjBMI
Number of subjects: 850000
Study 33593781 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous landiolol infusion to reduce heart rate between 80 and 94 bpm
Number of subjects: 340
Study 33593781 — intervention group
Group type: COMPARATOR
Intervention: Usual care (according to international standards)
Number of subjects: 340
Study 33305993 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral oncolytic agents (OAs)
Number of subjects: 230
Study 35842975 — intervention group
Group type: EXPERIMENTAL
Intervention: CRASH score (derived from 312,393 patients in the derivation set)
Number of subjects: 624786
Study 35842975 — intervention group
Group type: EXPERIMENTAL
Intervention: CRASH score validation
Number of subjects: 624786
Study 33719448 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-fat dairy milk
Number of subjects: 7
Study 33719448 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-fat dairy milk
Number of subjects: 7
Study 33719448 — intervention group
Group type: COMPARATOR
Intervention: Glucose alone
Number of subjects: 7
Study 34598146 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic third ventriculostomy plus choroid plexus cauterization
Number of subjects: 0
Study 34598146 — intervention group
Group type: COMPARATOR
Intervention: Ventriculoperitoneal shunt
Number of subjects: 0
Study 34598146 — intervention group
Group type: EXPERIMENTAL
Intervention: Subdural collections presence
Number of subjects: 0
Study 34598146 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayley-III cognitive score
Number of subjects: 0
Study 34598146 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative CSF volume
Number of subjects: 0
Study 34598146 — intervention group
Group type: EXPERIMENTAL
Intervention: Causal mediation analysis
Number of subjects: 0
Study 34487441 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal insulin plus GLP-1 RA
Number of subjects: 0
Study 34487441 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal insulin plus SGLT2 inhibitor
Number of subjects: 0
Study 34487441 — intervention group
Group type: COMPARATOR
Intervention: Basal-bolus insulin intensification
Number of subjects: 0
Study 35568679 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin in COU-AA-301-AAP
Number of subjects: 0
Study 35568679 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin in COU-AA-302-AAP
Number of subjects: 0
Study 35568679 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin in COU-AA-302-P
Number of subjects: 0
Study 35568679 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin pooled analysis
Number of subjects: 0
Study 35568679 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins in COU-AA-301-AAP
Number of subjects: 0
Study 35568679 — intervention group
Group type: COMPARATOR
Intervention: Statins in COU-AA-301-P
Number of subjects: 0
Study 35568679 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins in COU-AA-302 groups
Number of subjects: 0
Study 35568679 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins pooled analysis
Number of subjects: 0
Study 33745697 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Task Analysis (CTA) learning tool
Number of subjects: 14
Study 33745697 — intervention group
Group type: COMPARATOR
Intervention: Standard operative technique manual for antegrade femoral intramedullary nailing (Control)
Number of subjects: 14
Study 35951432 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol chewing gum (one piece for 15 minutes, 3 times daily)
Number of subjects: 60
Study 35951432 — intervention group
Group type: COMPARATOR
Intervention: Standard postoperative care (control group)
Number of subjects: 60
Study 33443117 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaboxadol 15 mg evening dose (qd)
Number of subjects: 88
Study 33443117 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaboxadol 10 mg morning dose and 15 mg evening dose (bid)
Number of subjects: 88
Study 33443117 — intervention group
Group type: COMPARATOR
Intervention: Placebo morning dose and evening dose
Number of subjects: 88
Study 32870155 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol medium-chain triglyceride (MCT)
Number of subjects: 30
Study 32870155 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol long-chain triglyceride (LCT)
Number of subjects: 30
Study 32870155 — intervention group
Group type: EXPERIMENTAL
Intervention: Both propofol MCT and LCT preparations
Number of subjects: 30
Study 35812088 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabiximols oromucosal spray
Number of subjects: 34
Study 35812088 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 35403393 — intervention group
Group type: EXPERIMENTAL
Intervention: Fang's scalp acupuncture combined with conventional acupuncture
Number of subjects: 66
Study 35403393 — intervention group
Group type: COMPARATOR
Intervention: Conventional acupuncture
Number of subjects: 66
Study 34115329 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 0
Study 34115329 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 0
Study 34115329 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor (Asian sub-population outcomes)
Number of subjects: 0
Study 33430665 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (Calcium Channel Blocker)
Number of subjects: 210
Study 34170188 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release naltrexone
Number of subjects: 570
Study 34170188 — intervention group
Group type: COMPARATOR
Intervention: Buprenorphine-naloxone
Number of subjects: 570
Study 34578782 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy intake
Number of subjects: 142
Study 34578782 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein intake
Number of subjects: 142
Study 34578782 — intervention group
Group type: EXPERIMENTAL
Intervention: VDR gene polymorphism (rs11568820 and rs4516035)
Number of subjects: 142
Study 33248625 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-calcium diet (1.5%)
Number of subjects: 72
Study 33248625 — intervention group
Group type: COMPARATOR
Intervention: Control calcium diet
Number of subjects: 72
Study 36250317 — intervention group
Group type: EXPERIMENTAL
Intervention: VAC (vincristine-dactinomycin-cyclophosphamide)
Number of subjects: 172
Study 36250317 — intervention group
Group type: EXPERIMENTAL
Intervention: VAI (vincristine-dactinomycin-ifosfamide)
Number of subjects: 172
Study 36250317 — intervention group
Group type: COMPARATOR
Intervention: VAC
Number of subjects: 172
Study 36250317 — intervention group
Group type: COMPARATOR
Intervention: VAI
Number of subjects: 172
Study 33597580 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (200 mg doses administered via chewing gum, four doses during night-time)
Number of subjects: 0
Study 33597580 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study 32305930 — intervention group
Group type: EXPERIMENTAL
Intervention: MusicGlove (wearable grip sensor integrated with a musical computer game)
Number of subjects: 11
Study 32305930 — intervention group
Group type: EXPERIMENTAL
Intervention: MusicGlove
Number of subjects: 11
Study 35192908 — intervention group
Group type: EXPERIMENTAL
Intervention: iBond® Universal in self‐etch mode (iBU‐SE)
Number of subjects: 50
Study 35192908 — intervention group
Group type: EXPERIMENTAL
Intervention: iBond® Universal in selective‐enamel-etch mode (iBU‐SEE)
Number of subjects: 50
Study 35192908 — intervention group
Group type: EXPERIMENTAL
Intervention: iBond® Universal in etch‐and‐rinse mode (iBU‐ER)
Number of subjects: 50
Study 35192908 — intervention group
Group type: COMPARATOR
Intervention: OptiBond™ FL (OFL)
Number of subjects: 50
Study 35192908 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (iBU and OFL)
Number of subjects: 50
Study 35192908 — intervention group
Group type: EXPERIMENTAL
Intervention: iBU‐SE vs. iBU‐SEE
Number of subjects: 50
Study 35192908 — intervention group
Group type: EXPERIMENTAL
Intervention: iBU‐ER vs. iBU‐SE
Number of subjects: 50
Study 35192908 — intervention group
Group type: EXPERIMENTAL
Intervention: iBU‐ER vs. OFL
Number of subjects: 50
Study 35192908 — intervention group
Group type: EXPERIMENTAL
Intervention: iBU vs. OFL at dentin/cement
Number of subjects: 50
Study 35192908 — intervention group
Group type: EXPERIMENTAL
Intervention: iBU‐SE vs. iBU‐ER
Number of subjects: 50
Study 33822798 — intervention group
Group type: EXPERIMENTAL
Intervention: Moringa oleifera capsule
Number of subjects: 0
Study 33822798 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35570039 — intervention group
Group type: EXPERIMENTAL
Intervention: 7% iodine tincture umbilical dip (n = 140)
Number of subjects: 284
Study 35570039 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group, n = 144)
Number of subjects: 284
Study 35570039 — intervention group
Group type: EXPERIMENTAL
Intervention: 7% iodine tincture umbilical dip
Number of subjects: 284
Study 33761901 — intervention group
Group type: EXPERIMENTAL
Intervention: US-guided bilateral posterior TAPB with RSB (40 mL 0.33% ropivacaine + 20 mL 0.33% ropivacaine)
Number of subjects: 78
Study 33761901 — intervention group
Group type: EXPERIMENTAL
Intervention: US-guided bilateral posterior TAPB alone
Number of subjects: 78
Study 33761901 — intervention group
Group type: COMPARATOR
Intervention: Saline alone (Control Group)
Number of subjects: 78
Study 35292085 — intervention group
Group type: EXPERIMENTAL
Intervention: 38% silver diamine fluoride (SDF) applied for varying times (3, 5, 10, 15, 30, 45, 60, 120, and 180 seconds)
Number of subjects: 414
Study 35292085 — intervention group
Group type: COMPARATOR
Intervention: 38% silver diamine fluoride (SDF)
Number of subjects: 414
Study 33875729 — intervention group
Group type: EXPERIMENTAL
Intervention: cathodal tDCS during aerobic exercise
Number of subjects: 122
Study 33875729 — intervention group
Group type: COMPARATOR
Intervention: cathodal tDCS alone
Number of subjects: 122
Study 33875729 — intervention group
Group type: COMPARATOR
Intervention: anodal tDCS during aerobic exercise
Number of subjects: 122
Study 33875729 — intervention group
Group type: COMPARATOR
Intervention: anodal tDCS alone
Number of subjects: 122
Study 33875729 — intervention group
Group type: COMPARATOR
Intervention: aerobic exercise
Number of subjects: 122
Study 33875729 — intervention group
Group type: COMPARATOR
Intervention: active control during aerobic exercise
Number of subjects: 122
Study 35982258 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 0
Study 35982258 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34781915 — intervention group
Group type: EXPERIMENTAL
Intervention: Training group (n=508)
Number of subjects: 1079
Study 34781915 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation group (n=507)
Number of subjects: 1079
Study 34781915 — intervention group
Group type: EXPERIMENTAL
Intervention: Model developed using six variables
Number of subjects: 1079
Study 32604406 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimodivir 600 mg plus oseltamivir 75 mg twice daily for 7 days
Number of subjects: 0
Study 32604406 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus oseltamivir 75 mg twice daily for 7 days
Number of subjects: 0
Study 33662625 — intervention group
Group type: EXPERIMENTAL
Intervention: High-confidence SV calls established using multiple technologies (109× PacBio CLR, 22× PacBio CCS, 104× Oxford Nanopore long reads, 114× optical mapping platform, and one de novo assembly-based SV caller using CCS reads)
Number of subjects: 0
Study 33662625 — intervention group
Group type: EXPERIMENTAL
Intervention: Trio-binning based haplotype assemblies
Number of subjects: 0
Study 32678716 — intervention group
Group type: EXPERIMENTAL
Intervention: Neratinib (240 mg once daily) plus capecitabine (750 mg/m2 twice daily for 14 days of a 21-day cycle)
Number of subjects: 621
Study 32678716 — intervention group
Group type: COMPARATOR
Intervention: Lapatinib (1,250 mg once daily) plus capecitabine (1,000 mg/m2 twice daily for 14 days of a 21-day cycle)
Number of subjects: 621
Study 32678716 — intervention group
Group type: EXPERIMENTAL
Intervention: Neratinib plus capecitabine
Number of subjects: 621
Study 32678716 — intervention group
Group type: COMPARATOR
Intervention: Lapatinib plus capecitabine
Number of subjects: 621
Study 36162897 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver Diamine Fluoride (SDF) application before ART restorations
Number of subjects: 194
Study 36162897 — intervention group
Group type: COMPARATOR
Intervention: Placebo (tonic water) application before ART restorations
Number of subjects: 194
Study 35902652 — intervention group
Group type: EXPERIMENTAL
Intervention: Inosine
Number of subjects: 120
Study 35902652 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 120
Study 34158069 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent hypoxia (IH) for 6 hours after a meal
Number of subjects: 15
Study 34158069 — intervention group
Group type: COMPARATOR
Intervention: Normoxia for 6 hours after a meal
Number of subjects: 15
Study 35000803 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-benefit group
Number of subjects: 269
Study 35000803 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk-sharing group
Number of subjects: 269
Study 35000803 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 269
Study 33272281 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent preventive treatment in pregnancy (IPTp) with dihydroartemisinin–piperaquine (DP)
Number of subjects: 656
Study 33272281 — intervention group
Group type: COMPARATOR
Intervention: Active PM
Number of subjects: 656
Study 33272281 — intervention group
Group type: COMPARATOR
Intervention: Severe past PM
Number of subjects: 656
Study 33272281 — intervention group
Group type: COMPARATOR
Intervention: Mild-moderate past PM
Number of subjects: 656
Study 33272281 — intervention group
Group type: COMPARATOR
Intervention: No PM
Number of subjects: 656
Study 34982628 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized telephone calls from service center representatives
Number of subjects: 79522
Study 34275096 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose dexamethasone (20 mg daily for 5 days, followed by 10 mg daily for 5 days)
Number of subjects: 98
Study 34275096 — intervention group
Group type: COMPARATOR
Intervention: CVD
Number of subjects: 98
Study 33129261 — intervention group
Group type: EXPERIMENTAL
Intervention: PROfit basic group (functional strength, balance, flexibility, and walking exercises at the same location)
Number of subjects: 513
Study 33129261 — intervention group
Group type: EXPERIMENTAL
Intervention: PROfit plus group (similar exercises as PROfit basic but changing locations)
Number of subjects: 513
Study 33129261 — intervention group
Group type: EXPERIMENTAL
Intervention: PROfit orientation group (navigation tasks in addition to relocation during the intervention)
Number of subjects: 513
Study 33129261 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 513
Study 33818302 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT‐based Complicated Grief Treatment (CGT)
Number of subjects: 131
Study 33818302 — intervention group
Group type: COMPARATOR
Intervention: Interpersonal Therapy (IPT)
Number of subjects: 131
Study 34819047 — intervention group
Group type: EXPERIMENTAL
Intervention: Violence prevention only
Number of subjects: 0
Study 34819047 — intervention group
Group type: EXPERIMENTAL
Intervention: Violence prevention and education
Number of subjects: 0
Study 34819047 — intervention group
Group type: EXPERIMENTAL
Intervention: Violence prevention, education and health
Number of subjects: 0
Study 34819047 — intervention group
Group type: EXPERIMENTAL
Intervention: Violence prevention, education, health and wealth creation
Number of subjects: 0